Nirmatrelvir and Ritonavir combination in COVID-19 patients with advanced chronic kidney disease
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - (2023) vom: 30. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lafont, Emmanuel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 30.12.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/cid/ciad785 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366496867 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366496867 | ||
| 003 | DE-627 | ||
| 005 | 20240108140952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciad785 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1246.xml |
| 035 | |a (DE-627)NLM366496867 | ||
| 035 | |a (NLM)38159041 | ||
| 035 | |a (PII)ciad785 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lafont, Emmanuel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nirmatrelvir and Ritonavir combination in COVID-19 patients with advanced chronic kidney disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Nirmatrelvir/ritonavir | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a hemodialysis | |
| 650 | 4 | |a pharmacokinetics | |
| 700 | 1 | |a Blez, Damien |e verfasserin |4 aut | |
| 700 | 1 | |a Bildan, Marc-Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Veyer, David |e verfasserin |4 aut | |
| 700 | 1 | |a Péré, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Puech, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Kably, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Cheminet, Geoffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Pouchot, Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Thervet, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Peytavin, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a Lazareth, Helene |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g (2023) vom: 30. Dez. |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:30 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciad785 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 30 |c 12 | ||